Combining incretin-based therapies with insulin: Realizing the potential in type 2 diabetes

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Vora, Jiten ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; CARDIOVASCULAR RISK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT SATISFACTION; WEIGHT GAIN; WEIGHT REDUCTION;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; TREATMENT OUTCOME;

EID: 84888607940     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2036     Document Type: Article

References (43)

1. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010;123(Suppl.): S19-S27
2. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-165
3. Tews D, Werner U, Eckel J. Enhanced protection against cytokine-and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008;40:172-180
4. Bosi E. Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab 2010;95:2607-2609
5. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511-1523
6. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-112
7. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hy-poglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41-46
8. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011;13:592-595
9. Yabe D, Watanabe K, Sugawara K, et al. Comparison of incretin immunoassays with or without plasma extraction: in-cretin secretion in Japanese patients with type 2 diabetes. J Diabetes Invest 2012;3: 70-79
10. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14: 910-917
11. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in mono-therapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-1231
12. Rosenstock J, Forst T, Aronson R, et al. Efficacy and safetyof once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes: GetGoal-Duo 1 Study (Abstract). Diabetes 2012;61 (Suppl. 1):A18
13. Riddle MC, Home P, Marre M, Niemoeller E, Ping L, Rosenstock J. Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin 6 metformin: GetGoal-L Study (Abstract). Diabetes 2012;61(Suppl. 1): A251
14. Rosenstock J, Ahrén BO, Chow FC, et al. Once-weekly GLP-1 receptor agonist al-biglutide vs. titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (T2D) uncontrolled on glargine S231 plus oral agents: similar glycemic control with weight loss and less hypoglycemia (Abstract). Diabetes 2012;61(Suppl. 1): A15
15. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-1155
16. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypogly-cemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40:427-430
17. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypo-glycaemia. Diabetes Obes Metab 2009;11: 1145-1152
18. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-177
19. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as addon therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012;14:795-802
20. Riddle M, Ahmann A, Basu A, Aroda V, Ratner R. Metformin+exenatide+basal insulin vs metformin+placebo+basal insulin: reaching A1c, 6.5% without weight-gain or serious hypoglycemia (Abstract). Diabetes 2010;57(Suppl. 1):LB6
21. DeVries JH, Bain SC, Rodbard HW, et al.; Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012;35:1446-1454
22. Blevins TC, Arakaki RF, Liljenquist DR. Once-daily basal insulin added to oral antihyperglycemic medications (OAMs) and exenatide (Ex) improves glycemic control in patients (Pts) with type 2 diabetes (T2D) (Abstract). Diabetes 2010;57(Suppl. 1):LB6
23. Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 2011;13:268-275
24. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetesdcauses, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
25. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
26. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687-694
27. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes. Endocr Pract 2012;18:17-25
28. Thong KY, Jose B, Sukumar N, et al.; ABCD Nationwide Exenatide Audit Contributors. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Dia-betologists nationwide exenatide audit. Diabetes Obes Metab 2011;13:703-710
29. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral anti-diabetes agents. Diabetes Care 2007;30: 2767-2772
30. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258, e22
31. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglu-tide versus sitagliptin for patients with type 2diabeteswho did nothave adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
32. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34(Suppl. 2):S279-S284
33. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113
34. Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2628-2635
35. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of ex-enatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100
36. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
37. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
38. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
39. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012;55:915-925
40. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25
41. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616
42. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-2012
43. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypo-glycemia in type 2 diabetes. Am J Manag Care 2011;17:673-680